Cell mediated immunity in patients with Virchowian hanseniasis before and after treatment with transfer factor. 1980

P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz

Cell mediated immunity (CMI), bacterial index (BI), morphological index (MI), skin and lymph nodes biopsies were evaluated in 15 patients with virchowian hanseniasis before and after treatment with transfer factor (TF) obtained from human spleens. The patients were divided in 3 groups: group I (control) received only sulfone, group II received sulfone plus TF and group III received only TF. There was no difference in the numbers of peripherical T and B lymphocytes of patients and normal controls. Before the treatment with TF, there was an impaired response of the patient's peripheral lymphocytes to PHA stimulus, in the presence of autologous or homologous plasma. This depressed response was corrected after treatment with TF in the patients of group III. In none of the patients a positive Mitsuda reaction was observed before and after treatment with TF. The improvement of the MI observed in group III, treated only with TF was remarkably similar to the patients treated only with sulfone. This work points out that TF has a role in the treatment of patients with virchowian hanseniasis, based on the improvement of CMI, MI, on histopathology of skin biopsies and clinical conditions.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007918 Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. Hansen's Disease,Hansen Disease
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
April 1974, Cellular immunology,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
May 1989, Parasite immunology,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
January 1976, Giornale di clinica medica,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
July 1976, British medical journal,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
January 1989, Medicina cutanea ibero-latino-americana,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
July 1983, The Japanese journal of surgery,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
July 1981, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
November 1979, Cellular immunology,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
September 1977, Clinical immunology and immunopathology,
P G Leser, and L Margarido, and W Belda, and S G Sartori, and W A Hares, and C A Freire, and R Fleury, and M R Montenegro, and W Leser, and C K Naspitz
May 1999, Hepato-gastroenterology,
Copied contents to your clipboard!